Key Takeaways
Oric Pharmaceuticals (NASDAQ: ORIC) is the subject of an investigation by Pomerantz LLP after its stock price fell 41 percent following a disappointing update on its lead drug candidate.
The law firm announced on May 14, 2026, that it is investigating claims of securities fraud or other unlawful business practices on behalf of investors.
Oric's stock dropped $5.20 per share to close at $7.48 on April 1, 2026. The decline occurred after the company issued a press release on March 31 with an update on its rinzimetostat (ORIC-944) prostate cancer treatment that failed to meet market expectations for best-in-class efficacy.
The investigation could precede a class-action lawsuit, which would seek to recover damages for investors. This legal action creates significant financial and reputational uncertainty for the pharmaceutical company as it moves forward.
The 41 percent single-day decline has erased significant market value, and the stock now trades at its lowest level since the announcement. Investors will be watching for the formal filing of a class-action lawsuit and any response from ORIC Pharmaceuticals' management.
This article is for informational purposes only and does not constitute investment advice.
